Scientific Poster
Immunocompetent Human Brain Organoids for Modeling Alzheimer’s Disease

Despite significant resources directed towards understanding the pathologies of Alzheimer’s disease (AD) and AD-related dementias, progress on developing drug candidates has been slow, and there are few approved treatments providing disease modifications. Using human induced pluripotent derived stem cells (iPSC), we have developed a scalable cortical organoid model (CNS-3D Brain Organoids) that exhibits robust, reproducible, and clinically relevant phenotypes.

While standard CNS-3D expresses the primary brain cell types (neurons and glia), we improved the technology by integrating microglia to enable the neuroinflammatory component critical to modeling Alzheimer’s Disease. CNS-3D Inflammatory Organoids (CNS-3D IO) were generated by seeding CNS-3D with isogenic microglia at 3 weeks of age.

The CNS-3D IO were then challenged with 3 different forms of amyloid-β (Aβ) and measured for functional activity (FLIPR calcium imaging) and cytokine profiling. Consistent with previous work in 2D, neuronal monocultures, Aβ oligomers were the most toxic of all Aβ forms. In CNS-3D IO, oligomers and fibrils of Aβ caused significant reductions in FLIPR peak frequency of CNS-3D IO, while Aβ monomers did not, and no form of Aβ affected this measure in standard CNS-3D. Furthermore, Aβ oligomers and fibrils reduced the amplitude and slope of FLIPR peaks, while Aβ monomers did not.

Cytokine analysis demonstrated that incorporation of microglia was required for activation of IL-1β and IL-10 by Aβ oligomers and fibrils. Utilizing AD-related insults, as well as genetic approaches, CNS-3D IO can now test many features of AD to bring promising drug candidates to the clinic faster while maintaining relevance to the human condition.

View Poster